



## **The clinical pharmacology review and research outcomes - *Progesterone in pregnancy maintenance***


**Paul PIETTE, PharmD**  
*Senior Research Fellow  
Scientific & Medical Affairs*  
Besins Healthcare  
Brussels - Belgium  
ppiette@besins-healthcare.com



**financial disclosure**

**Paul Piette, PharmD**  
**Scientific & Medical Affair**  
**Consultant for Besins Healthcare Global**

## What is TM and...why progesterone is so important during the all pregnancy...




- Miscarriage (M) is spontaneous loss of pregnancy before the fetus has reached viability, from the time of conception until 24 weeks of gestation.<sup>1</sup>
- TM is defined by vaginal bleeding (and pain) in a woman with a confirmed pregnancy.<sup>1</sup>
- Recurrent miscarriage is defined as three or more consecutive pregnancy losses, although many clinicians define it as 2 or more losses.<sup>2</sup>



1. Rai R, Regan L. Lancet 2006; 368: 601-611.  
 2. Griebel CP, Halvorsen J, Golemon TB, Day AA. 2005; 72: 1243-1250

## ETHIOLOGIC PATHWAYS leading to Preterm Birth



Rodts-Palenik et al. *Obstet Gynecol Survey* 2002; 57 (5): S9 – S34



## Role of progesterone in prevention of preterm birth

### *Mechanism of action*

## MYOMETRIAL RELAXATION AND CONTRACTION

- Progesterone induces high levels of cyclic Adenosine Mono Phosphate and time-dependent stimulation of Nitric Oxide Synthetase (NOS) <sup>1</sup>
- Progesterone inhibits formation of myometrial gap junctions (channels made of connexin 43) <sup>2</sup>
- Progesterone and its metabolites induce uterine quiescence through interactions between nuclear and membrane progesterone receptors <sup>3,4,5</sup>
- Progesterone maintains low levels of prostaglandins (via cyclooxygenase), oxytocin and intracellular calcium

1. Khorram O et al. *Fertil Steril* 2009; **91**: 2157-62


2. Garfield RE et al. *Am J Physiol* 1980; **238**: C81-9

3. Perusquía M et al. *Life Sci* 2001; **68**: 2933-44

4. Karteris E et al. *Mol Endocrinol* 2006; **20**: 1519-34

5. Merlino AA et al. *J Clin Endocrinol Metab* 2007; **92**: 1927-33

- Progesterone inhibits inflammatory responses associated with preterm parturition
- Progesterone promotes myometrial relaxation



➤ **Connexin 26**


- ✓ High during pregnancy
- ✓ ↓ onset of labor

➤ **Connexin 43 (45 – 40)**

- ✓ Low during pregnancy
- ✓ ↑ immediately before the onset of labor

Pierce et al. *Am J Obstet Gynecol* 2002; **186** (3): 504-11  
 Cluff et al. *Reprod Biol Endocrinol* 2006; **44**: 24

## How does Progesterone relax the Uterus in Pregnancy?




The combined actions of inhibitory transcription factors ZEB1 and ZEB2 (zinc finger E-box binding homeobox proteins 1 and 2) and members of the microRNA (miRNA)-200 family mediate the effect of progesterone on key contraction-associated proteins (CXN43 and OXTR) in the uterus during pregnancy.

The action of progesterone diminishes at the time of labor, and the steady state of the feedback loop drifts toward low ZEB levels and high miRNA-200 levels. ZEB1 and ZEB2 no longer inhibit CXN43 and OXTR, which increases myometrial contractility...

and stimulates the onset of labor.

Zakar T et al. *N Engl J Med* 2011; 364(10): 972-973


## CROSS-TALK between membrane and nuclear PRs



Karteris et al. *Mol Endocrinol* 2006; 20: 1519-1534

Wang R et al. *Reprod Fertil Dev.* 2014; 30. doi: 10.1071/RD13430.

## Theoretical model for the role of the myometrial ER and PR systems in the regulation of human pregnancy and parturition




Mesiano et al. *J Clin Endocrinol Metab* 2002; 87: 2924-2930

## Other effects of progesterone



### Effect on uterine contractility

### Neuroprotection of fetal brain




- Allopregnanolone is a neuroactive steroid
- Modulates GABAergic inhibition
- Control & balance fetal behaviour
- Protection of fetal brain from
  - hypoxia
  - ischemia

Hirst J et al *J Ster Biochem* 2014




## Contribution of enzyme pathways in the sheep placenta and foetal brain to allopregnanolone concentrations.



- Human studies suggest that the placenta contributes directly and indirectly to the allopregnanolone found in the circulation and potentially the foetal brain.
- The capacity of the maternal brain to generate neurosteroids is increased in pregnancy
- Allopregnanolone can modulate neuroendocrine responses to stress

Brunton et al. *Progress in Neurobiology* 2014; **113**: 106-136

## Allopregnanolone-opioid mechanisms involved in suppressed HPA axis responses in late pregnant rats.



**In pregnancy, allopregnanolone prevents activation of the CRH neurones, thereby inhibiting CRH release at the median eminence (ME) and preventing HPA axis responses to IL-1β.**

Brunton et al. *Progress in Neurobiology* 2014; **113**: 106-136

	Placebo group	Progesterone group	Unadjusted odds ratio (95% CI) or difference in means (95% CI)	p value (unadjusted)	Adjusted odds ratio (95% CI)* or difference in means (95% CI)	p value (adjusted†)
Fetal death or delivery <34 weeks of gestation	108/597 (18%)	96/600 (16%)	0.86 (0.64 to 1.17)	0.34	0.86 (0.61 to 1.22)	0.67
Neonatal morbidity or death	60/587 (10%)	39/589 (7%)	0.62 (0.41 to 0.94)	0.02	0.62 (0.38 to 1.03)	0.072
Cognitive composite score at 2 years††	97.7 (17.5)	97.3 (17.9)	-0.48 (-2.77 to 1.81)§	0.68	-0.48 (-2.77 to 1.81)§	0.68
Components of the obstetric outcome						
Fetal death	7/597 (1%)	8/600 (1%)	1.14 (0.41 to 3.17)	0.8	--	--
Liveborn delivery before 34 weeks	101/590 (17%)	88/592 (15%)	0.85 (0.62 to 1.15)	0.29	--	--
Components of the neonatal outcome						
Neonatal death	6/597 (1%)	1/600 (<1%)	0.17 (0.06 to 0.49)	0.0009¶	--	--
Bronchopulmonary dysplasia	18/574 (3%)	17/580 (3%)	0.94 (0.49 to 1.78)	0.84	--	--
Brain injury on ultrasound scan**	34/574 (6%)	18/584 (3%)	0.50 (0.31 to 0.84)	0.008	--	--

\* p unadjusted = 0.02 (statistically significant)

† p unadjusted for previous pregnancy of at least 14 weeks because of small sample size.

### Neonatal morbidity or death:

- **0.2% neonatal death** in progesterone group **1%** deaths in placebo group (***P=0.0009***)
- **3%** with brain injury in progesterone group and **6%** in placebo (***P=0.008***)

Norman et al. *Lancet* 2016. Published Online February 23, 2016  
[http://dx.doi.org/10.1016/S0140-6736\(16\)00350-0](http://dx.doi.org/10.1016/S0140-6736(16)00350-0)

## Long-term effects of prenatal progesterone exposure on neurophysiological development and hospital admissions in twins up to 8 years of age (PREDICT study)

### Ages Stages Questionnaire (ASQ) scores

**N=437 children** (progesterone, n=225; placebo, n=212).

**Mean Total ASQ score higher in the progesterone vs placebo**


**269,0 vs 261,7** ***P=0.03***

### In dichorionic twins

- Risk of having a low ASQ score (<10th centile) decreased in the progesterone group: **OR 0.34 (0.14;0.86)**
- Overall higher total mean score (***p=0.01***), higher mean score in communication (***p=0.04***), gross motor skills (***p=0.02***) and personal/social (***p=0.04***).


Vedel C et al. *Ultrasound Obstet Gynecol* 2016; 48: 382–389

## Progesterone Receptors (PR): A Key for Neuroprotection in Experimental Stroke



Liu A et al. *Endocrinology* 2012;153:3747-57

## Neuroprotective effects of progesterone




**Progesterone accelerates myelination in organotypic cultures of rat CNS**

**Progesterone promotes the remyelination of axons after cryolesion of the mouse sciatic nerve**

Schumacher 2003

## Oral Mic P4 and sleep EEG parameters \* (mean +/- SD)



\* before treatment (Baseline), at day 21 Placebo or Progesterone (300mg/d) treatment (*Utrogest caps*)  
 TST = Total Sleep Time  
 SPT = Sleep Period Time

Schüssler P et al. *Psychoneuroendocrinology* 2008; **33**: 1124-1131

## Oral Mic P4 prevents sleep disturbances

**Progesterone Prevents Sleep Disturbances and Modulates GH, TSH, and Melatonin Secretion in Postmenopausal Women**

Anna C. Caufriez, Sarah Verheyden, Ingrid L'Hermès-Balme, Myrtille Verheul, and Christophe L'Hermès. *J Clin Endocrinol Metab* 2011; **96**: E614-E623. doi:10.1210/jc.2010-2558

- Progesterone (P4) had no effect on undisturbed sleep
- P4 restored normal sleep when sleep was disturbed (P4 increases deep sleep while currently available hypnotics tend to inhibit deep sleep), acting
- P4 acts as a “physiologic” regulator rather than as a hypnotic drug.
- Use of progesterone might provide novel therapeutic strategies for the treatment of sleep disturbances, in particular in aging where sleep is fragmented and of lower quality.

Caufriez et al. *J Clin Endocrin Metab* 2011 2011, **96**, E614-E623. doi:10.1210/jc.2010-2558



## Progesterone and influence of the route of administration

### *Mechanism of action*


### Routes of administration

**ORAL**



- 90% metabolized after 1st hepatic passage
- High inter-individual variability
- rapid increase in plasma concentration followed by gradual decrease
- **metabolites 5- $\alpha$  & 5- $\beta$**  possess hypnotic and anxiolytic effects (via GABA rec)


**I.M.**



#### **Discomfort and painful injection**

- Supraphysiological blood levels
- At least twice weekly requiring nurse assistance
- Granulomas (>oil), allergy and dry abscesses
- Risk for acute eosinophilic pneumonia
- Choice between daily and "depot"

**VAG**



#### **VAG CAPS**

**Minimal or no discomfort**

→ **Constant systemic levels**

→ **Avoid hepatic passage, safest**

→ **1<sup>st</sup> uterine passage**

#### **VAG GEL**

Cloddy vaginal discharges

- Perineal pains (reported  $\geq$  5% patients)
- Painful or difficult intercourse, genital itching, genital yeast infection, urinary tract infection (reported in 1 to 5% of patients)

Plagiarized and adapted from **GC Di Renzo**, personal communication

## Metabolization of oral Natural Progesterone

Oral-administered progesterone undergoes several successive metabolisation steps:

- ✓ in the gut (bacteria with 5b-reductase activity)
- ✓ in the intestinal wall (5a-reductase activity)
- ✓ in the liver (5b-reductase, 3a-and 20a-hydroxylase activities)



5a-pregnanolone and 5b-pregnanolone (**GABA<sub>A</sub>**)  
 5a-pregnanedione and 5b-pregnanedione (**anti-mitotic, tocolytic**)

## Effect of progesterone and his metabolites on spontaneous uterine contractility of pregnant women at term





Fig. 3. Comparison of the relaxing effect induced by progestins at equimolar concentration (100 µM) on spontaneous uterine contractility of pregnant women at term. Each bar represents the mean ± SEM (n ≥ 6). \*p<0.003, \*\*p<0.0005, \*\*\*p<0.0001 vs. progesterone (P<sub>4</sub>). Note the effect of all progestins was significantly different (p<0.0001) vs. ethanol at 17.14 mM (0.1 %), a concentration identical to those use as solvent for progestins.

## Use of exogenous progesterone

### Vaginal administration (route)




First uterine pass effect / targeted delivery

Cicinelli E et al, *Obstet Gynecol* 2000; 95: 403-6


## Use of exogenous progesterone

### Pharmacokinetics data: vaginal route vs IM

Plasma progesterone concentrations in steady state



Progesterone concentrations in uterine tissue in steady state



Miles A et al, *Fertil Steril* 1994; 62: 485-90

## Characteristics of Mic P4 versus synthetic Progestogens

Natural Micronized Progesterone (MP)

=

Exact chemical duplicate of Progesterone  
produced by the human body

≠

**Synthetic analogues of Progesterone  
labeled *Progestogens* or *Progestins***

## Major Differences in *Pharmacodynamics* of Micronized progesterone versus synthetic progestins

- Tranquilizing effect
- Anti-androgenic effect
- Diuretic effect

## Synthetic progestins

- Synthetic analogues of Progesterone have been developed to make the hormone available orally
- First developed for use as contraceptive agent
- Many of these compounds bind to receptors for glucocorticoids, androgen and mineralocorticoids

→ side effects (acne, weight gain, depression, mood swings, irritability)

## Natural Progesterone vs Synthetic progestins


Pregnanolone metabolites are physiological  
anxiolytic and hypnotic steroids  
Interacting with GABA<sub>A</sub> receptor in CNS

≠

Synthetic progestins are not pro-drugs for these metabolites  
Negative effect on mood

No anxiolytic, sedative, hypnotic effect


## Oral Mic P4 and tranquilizing effect



### Efficacy of oral Mic P4 in Premenstrual Syndrome treatment

Dennerstein L et al. *Br Med J* 1985; 290: 1617-1621

## Dydrogesterone versus Progesterone



Dydrogesterone is a retroprogesterone,  
 a stereoisomer of progesterone:

1.  $H_{30}$  instead of  $H_{28}$  in progesterone:  $C_{21}H_{30}O_2$  vs  $C_{21}H_{28}O_2$
2. No Double bond in C 6-7
3. Progesterone is a **flat (and not truncated)** molecule
4. Progesterone does not bind same receptors

## Treatment of premenstrual Syndrome A double-blind Trial of dydrogesterone

### Summary


A double-blind randomised crossover trial of oral micronised progesterone and placebo had demonstrated that progesterone had beneficial effects over placebo for some mood and physical premenstrual symptoms. A further trial using identical methodology was carried out to assess whether dydrogesterone would have the same beneficial effects. Prospective assessment confirmed the presence of a premenstrual syndrome in 30 women. Of these, six withdrew during the 4 months of the study. Twenty-four women completed the double-blind crossover protocol. All women were interviewed premenstrually before treatment and in each month of treatment. They completed the Moos Menstrual Distress Questionnaire, Beck Depression Inventory, Spielberger State Anxiety Inventory, Mood Adjective Checklist and a Daily Symptom Record. Analysis of data found an overall beneficial effect of being treated for most variables. Further analysis showed that the most major effects occurred in the first 2 treatment months. This study could find no evidence that dydrogesterone was more effective than placebo in treating premenstrual complaints.

**This study could find no evidence that dydrogesterone was more effective than placebo in treating premenstrual complaints**


Dennerstein et al. *Journal of Affective Disorders* 1986; 11: 199-205

## Progestogen


### Three Different Compounds



P4



17-OHP




17-OHP-C

Natural compounds

Synthetic

## Tocolytic effect of progesterone versus synthetic progestins

Changes in contractility in progesterone and 17 OH-progesterone treated myometrial strips <sup>2</sup>



- Progesterone reduces myometrial oxytocin-induced contraction <sup>1</sup>
- Progesterone, but not 17 OH-progesterone, directly inhibits uterine contractility <sup>2,3</sup>
- 17P did not delay the interval to delivery in women with tocolysis-arrested preterm labor <sup>4,5</sup>

1. Chanrachakul B et al. *Am J Obstet Gynecol* 2005; 192: 458-63. 2. Ruddock NK et al. *Am J Obstet Gynecol* 2008; 199: 391-7. 3. O'Brien JM et al. *Am J Perinatol* 2010; 27: 157-62. 4. Briery C et al. *J Mat Fet Neonat Med* 2014. doi: 10.3109/14767058.2014.892922. 5. Rozenberg P et al. *Am J Obstet Gynecol* 2012; 206. e1-9.

## Progesterone is given prophylactically to prevent preterm birth among women

- Meis et al, 2003. *N Engl J Med*
- Da Fonseca et al, 2003. *Am J Obstet Gynecol*
- **Fonseca et al, 2007. *N Engl J Med***
- O'brien et al, 2007. *Ultrasound Obstet Gynecol*
- DeFranco et al, 2007. *Ultrasound Obstet Gynecol*
- Rai et al, 2009. *Int J Gynecol Obstet*
- Mahji et al, 2009. *J Obstet Gynecol*
- Cetingoz et al, 2009. *Arch Gynecol Obstet*
- **Hassan et al, 2011. *Ultrasound Obstet Gynecol***
- Rode et al, 2011. *Ultrasound Obstet Gynecol*
- Maher MA et al, 2013. *Acta Obstet Gynecol Scand*
- **Norman J et al, 2016. *The Lancet***

## Challenges in preterm delivery prevention and management

### Identification of risk factors

*Prior history of preterm birth*

*Twin pregnancy*

*Short cervix at scan*

TVS-cervical length is the single most powerful predictor for PTD in the index pregnancy.

### Strategy in the prevention

Progesterone



Cerclage



Pessary




On the courtesy of Eduardo Fonseca

## Challenges in preterm delivery prevention and management

### Strategy in the prevention

**Short cervix**




<25 mm

No prior  
PTD

Twins plus  
Short CxL

Prior PTD  
Plus Short  
CxL

## Effect of vaginal progesterone on preterm birth $\leq 34$ weeks of gestation




**CONCLUSION:** Vaginal progesterone administration to asymptomatic women with singleton gestation and a sonographic short cervix decreases preterm birth  $\leq 34$  weeks of gestation, neonatal morbidity and mortality.

Romero R et al. *Ultrasound Obstet Gynecol* 2016; **48**(3): 308-17


## Challenges in preterm delivery prevention and management

Strategy in the prevention



On the courtesy of Eduardo Fonseca

## Effect of vaginal progesterone on preterm birth in twin gestation



**CONCLUSION: Administration of vaginal P4 to asymptomatic women with a twin gestation and a sonographic short cervix in the mid-trimester reduces the risk of preterm birth occurring at < 30 to < 35 gestational weeks, neonatal mortality and some measures of neonatal morbidity, without any demonstrable deleterious effects on childhood neurodevelopment.**

Romero R et al. *Ultrasound Obstet Gynecol* 2017; **49(3)**: 303-14

## Challenges in preterm delivery prevention and management

Strategy in the prevention

Short cervix



<25 mm

No prior  
PTD

Twins plus  
Short CxL

Prior PTD  
Plus Short  
CxL

### Prior PTB and short cervix



Vaginal progesterone vs cervical cerclage for the prevention of preterm birth in women with a sonographic short cervix, previous preterm birth, and singleton gestation: a systematic review and indirect comparison metaanalysis

	Cerclage	Progesterone
Del <35 wks	↓ 33%	↓ 41%
Composite morbidity	↓ 40%	↓ 70%
Perinatal mortality	↓ 35%	↓ 27%

The selection of the optimal treatment may depend upon adverse events, cost and patient/clinician preferences.

Conde-Agudelo, et al. *Am J Obstet Gynecol* 2013; **208**: 1-42.

## CONCLUSION

- The **role of progesterone** in the **physiopathology of pregnant women** is **crucial** from conception until delivery.
- There is **strong biological plausibility** to support exogenous progesterone for the management of prevention of preterm birth in women at risk with a short cervix and/or a history of preterm delivery.
- The **optimal** dose, **route of administration** and **duration** remains to be determined in **symptomatic women** and in **pregnancy maintenance after tocolysis**.
- **Neonatal effects, health infant** and cost-effectiveness with vaginal micronized progesterone are now available with a level 1 of evidence.

## ***FUTURE PERSPECTIVES***

- Allopregnanolone has important roles during pregnancy in **quelling the responsiveness of the body's major neuroendocrine stress response system, the HPA axis.**
- Allopregnanolone restrains responses of neurons that make and secrete oxytocin to stimulate uterine contractions during birth; this action of allopregnanolone is considered **to help prevent preterm births.**
- The actions of allopregnanolone on oxytocin neurons are partly direct, **on GABA<sub>A</sub> receptors**, and partly indirect through **induction of an opioid peptide inhibitory mechanism** in the brainstem, in the noradrenergic pathway that conveys neural signals from the uterus.
- The **foetal brain** is also exposed to, and produces allopregnanolone, **reducing the impact of hypoxia**, which may be experienced during a difficult birth, and result in excitotoxic brain damage.
- Preterm birth has similar consequences, and the reduced allopregnanolone production in the brain **continues after birth, with impaired myelination and neuro behavioral outcomes.**